Reprogramming Myeloid Cells Enhances the Power of T-Cell Immunotherapy
Researchers have discovered that targeting PD-L1 recycling in myeloid cells enhances T-cell activation and boosts the effects of checkpoint blockade therapies.
A new antibody, H1A, shows promise for improving treatment outcomes.
Key Findings
- Mayo Clinic researchers identified myeloid cells as a target to boost standard immunotherapies for cancer.
- Two research teams found that manipulating myeloid cells can enhance the activity of tumor-killing T cells.
Enhanced myeloid cells may boost certain immune checkpoint therapies, which are the standard of care for some cancers but may not have lasting effects.
Author summary: Researchers enhance T-cell immunotherapy by reprogramming myeloid cells.